Biotec Pharmacon finalises Post Market study on Woulgan

Biotec Pharmacon finalises Post Market study on Woulgan

Tromsø, Norway, 29 January 2019 - Biotec Pharmacon's (OSE: Biotec) has announced
that its subsidiary, Biotec BetaGlucans, has finalised treatment in a UK Post
Market Clinical Follow-up (PMCF) study on its wound care gel, Woulgan®, in
diabetic foot ulcer patients.
Biotec BetaGlucans filed an application to the UK Medicines and Healthcare
Products Regulatory Agency (MHRA) in June 2018 to finalise the study. The
application was accepted in November 2018 and all patients have now been

The study, initiated in 2015, was part of the MHRA's requirements to assess the
safety and usefulness of Woulgan® before approval as a medical device in the
management of wounds. The study aimed to recruit 60 patients for treatment with
Woulgan® gel and 20 with a commercial hydrogel from Smith & Nephew (Intrasite®).
The study was allowed to be finalised after having recruited just above 60
patients in total.

In parallel with this study, Biotec Pharmacon ran a large 300-patient clinical
study in the UK (including diabetic patients), demonstrating the Woulgan® gel's
excellent safety profile and its clinical efficacy and usability. This evidence,
alongside case studies, has contributed to the MHRA's favourable decision to
allow the completion of the PMCF study.

The Contract Research Organisation handling the study is now collecting and
evaluating the data from the four clinical investigation sites. The results are
expected in late Q2 2019.

Christian Jørgensen, CEO, said:

"The acceptance from the MHRA and study completion is a positive step forwards
for the Company. These results expected mid-year will provide further validation
of our Woulgan® gel product in wound care management."

- Billedet er veldefineret = de kender til aktørerne, herunder BIOTEC = naturligvis kender de Biotec, hvor 2 tidligere ansatte har haft deres gang..
- Ikke noget konkret i gang = de er ligeglade med BIOTEC eller = Coloplast holder "kortene" tæt ind til kroppen og kender spillets regler

Om de så køber Biotec eller et andet selskab med sårplejeprodukter må tiden vise.